Main Menu
11
Aug
2005

CRUK Scientists Develop Stealth Anti-Cancer Drugs

 

Thursday 11 August 2005

 

CANCER RESEARCH UK funded scientists have developed a series of powerful stealth anti-cancer drugs that can sneak into tumours and destroy them, without causing damage to surrounding healthy cells, a study published in the Journal of Medicinal Chemistry reveals today*.

The research, carried out by scientists at The Institute of Cancer Research, showed that the drugs substantially delayed tumour growth in experiments on human breast cancer cells and in rodent animal models.  This research could lead to improved treatment and survival for cancer patients in the future.

The therapy involves sending a ‘scout’ enzyme to a tumour so marking it for destruction.  The enzyme is designed to attach and infiltrate only cancerous cells.  Here the enzyme lays dormant until non-toxic drugs, called prodrugs, are given.  These prodrugs only become active when they react with the ‘scout’ enzyme in the cancerous cell.  The enzyme acts as a switch to turn the harmless prodrug molecules, into a potent cancer killing drug.

The research team, led by Professor Caroline Springer, looked at how these drug compounds work in the method of drug delivery called gene-directed enzyme prodrug therapy (GDEPT). 

Standard cancer treatments, such as chemotherapy, treat cancer anywhere in the body by indiscriminately attacking all cells in the region.  The treatment damages healthy cells as well as cancerous ones, which is why patients have side effects.  These can include nausea, fatigue and hair loss.  In GDEPT, normal cells should not be affected by the treatment, and this could mean fewer side effects for patients in the future.

Previous prodrugs of this type have often not been powerful enough to reach the enzyme that has been sent to the affected cell.  What is unique about this study is that the scientists have been able to get the prodrugs to cross through the cell’s membrane into the cell itself more efficiently.

The researchers tested the eight prodrugs on three variants of human breast cancer.  Six of the compounds were found to be effective in targeting the affected cell lines, with three being particularly effective in delaying tumour cell growth.

The six positive compounds were then tested in animal models.  Two compounds resulted in a substantial delay to tumour development, and another two cured two models of their tumours.

Professor Caroline Springer, of the Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, says: "We think these drugs are a very promising way forward for cancer treatment.  They allow you to deliver a drug at a high concentration, which you wouldn’t normally be able to do, as it is too toxic for the rest of the body.  Although this treatment is more complex than many types of therapies, the fact that it can be so selective in treating cancer means that it is worth exploring further.

“At least one of the eight drugs we developed has been identified as a good candidate for testing GDEPT in clinical trials."

Professor Springer adds: "The key importance of this work lies in expressing the ‘scout’ enzyme, which enables the drugs to be selective as to which cells they target."

Professor John Toy, Medical Director at Cancer Research UK, says:  “Prodrugs potentially offer a localised treatment for cancer that allows drugs to be targeted specifically to tumours.  This type of therapy should theoretically work and is showing promise. Identifying further drugs as targets for GDEPT is an important step if this treatment is to become a viable reality for patients in the future. 

"The benefits that this therapy could offer, in terms of more comfortable treatment and reduced side effects, could greatly improve the quality of life for people living with cancer or allow larger doses to be prescribed.  The real test will come when the prodrugs go to clinical trials and we are able to analyse closely how well the treatment works in patients."

 

- ends -

 

For more information, please contact:
Cancer Research UK Press Office, 020 7061 8300

Out of hours duty press officer, 07050 264 059.

The Institute of Cancer Research
Tel: 0207 153 5359
email: [email protected]

Notes to editors

*Novel Fluorinated Prodrugs for Activation by Carboxypeptidase G2 Showing Good in Vivo Antitumor Activity in Gene-Directed Enzyme Prodrug Therapy.  Lawrence C. Davies, Frank Friedlos, Douglas Hedley, Jan Martin, Lesley M. Ogilvie, Ian J Scanlon, and Caroline J. Springer.  Journal of Medicinal Chemistry.  August 11 2005.  Volume 48, Issue 16, Pages 5321-5328.

The enzyme used in this study was carboxypeptidase G2 (CPG2, glutamate carboxypeptidase) derived from Pseudomonas RS16.

In GDEPT, the enzyme is targeted onto the tumour by a virus, or via a direct injection.

  • Cancer Research UK's vision is to conquer cancer through world-class research.
  • The charity works alone and in partnership with others to carry out research into the biology and causes of cancer, to develop effective treatments, improve the quality of life for cancer patients, reduce the number of people getting cancer and to provide authoritative information on cancer.
  • Cancer Research UK is the world's leading independent charity dedicated to research on the causes, treatment and prevention of cancer.
  • For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7121 6699 or visit www.cancerresearchuk.org
  • The Institute of Cancer Research is a centre of excellence with world leading scientists working on cutting edge projects. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis and treatment. Website at: www.icr.ac.uk
  • The Institute works in a unique partnership with the Royal Marsden, forming the largest comprehensive cancer centre in Europe. This relationship enables close daily contact with those on the frontline in the fight against cancer - the clinicians, the carers and most importantly, the patients.

 

Please note:
Unfortunately the press office are unable to answer queries from the general public. For general cancer information please refer to The Institute's cancer information page.

 

comments powered by Disqus
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.